SCHEMBL445256

SCHEMBL445256

O=C1[C]OC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514890 0.57
SCHEMBL3683928 0.57
SCHEMBL369085 0.53
Benzoquinone SCHEMBL28158877 0.50
Benzoquinone SCHEMBL28200370 0.50
SCHEMBL12158594 0.48 CA1 (0.32)
Maleic Anhydride SCHEMBL191 0.45
Maleic Anhydride SCHEMBL1332543 0.45
Maleic Anhydride SCHEMBL1761076 0.45 ALDH1A1 (0.37)
Maleic Anhydride SCHEMBL1332547 0.45

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177488-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF CIT THERAPEUTICS LLC 2022-06-09 US claimed
EP-3941905-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2022-01-26 EP claimed
WO-2020191151-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF ONCOVALENT THERAPEUTICS INC. (US) 2020-09-24 WO claimed
EP-1833826-B1 TRICYCLIC DELTA-OPIOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 EP claimed
EP-1798230-A1 Substituted alkylamine derivatives and methods of use Amgen Inc. (US) 2007-06-20 EP claimed
US-20060040956-A1 Substituted alkylamine derivatives and methods of use CHEN GUOQING 2006-02-23 US claimed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 US claimed
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-07-03 US claimed
US-5185320-A Antibiotics GRUPPO LEPETIT S.P.A. (IT) 1993-02-09 US claimed
US-20220177488-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF CIT THERAPEUTICS LLC 2022-06-09 US disclosed
EP-3941905-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2022-01-26 EP disclosed
WO-2020191151-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF ONCOVALENT THERAPEUTICS INC. (US) 2020-09-24 WO disclosed
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-20130273004-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-10-17 US disclosed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 US disclosed
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-07-03 US disclosed
WO-2002068406-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS AMGEN INC. (US) 2002-09-06 WO disclosed
WO-2002066470-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2002-08-29 WO disclosed
US-5185320-A Antibiotics GRUPPO LEPETIT S.P.A. (IT) 1993-02-09 US disclosed
EP-0391077-A1 O56-alkyl derivatives of aglycone and pseudoaglycones of teicoplanin GRUPPO LEPETIT S.p.A. (IT) 1990-10-10 EP disclosed